Medication Management for Anxiety and PTSD in Patients with Substance Use History

Primary Treatment Approach: Trauma-Focused Psychotherapy First

The American Psychological Association recommends trauma-focused psychotherapy as the first-line treatment, with Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), or Eye Movement Desensitization and Reprocessing (EMDR) showing 40-87% of patients no longer meeting PTSD criteria after 9-15 sessions 1, 2
These therapies are equally effective regardless of trauma type, childhood abuse history, or comorbidities, with no increased dropout rates even in complex presentations 3, 2
Relapse rates are substantially lower after completing CBT compared to medication discontinuation (26-52% relapse with sertraline discontinuation vs. lower rates post-CBT) 4, 1

Medication should be considered when psychotherapy is unavailable, the patient refuses psychotherapy, or residual symptoms persist after psychotherapy 4
The FDA-approved medications for PTSD, such as sertraline, paroxetine, or fluoxetine, are the exclusive pharmacological options in patients with substance use history, with SSRIs showing 53-85% of participants classified as treatment responders in controlled trials 4
Continue SSRI treatment long-term (at least 6-12 months after symptom remission) as discontinuation leads to high relapse rates 4

Benzodiazepines are absolutely contraindicated in patients with substance use history due to high abuse potential and evidence of worsening PTSD outcomes, with 63% of patients receiving benzodiazepines developing PTSD at 6 months compared to only 23% receiving placebo 1

Assess treatment response after 8 weeks of SSRI therapy; if inadequate response with good compliance, consider switching SSRIs or augmenting with trauma-focused therapy 2
Periodically reassess the need for continued pharmacotherapy, as psychotherapy may allow for eventual medication discontinuation with lower relapse risk 4, 1